2021 Annual Meeting
(56e) Tunable Enzymatic Synthesis of the Immunomodulator Lipid IVa to Enable Structure-Activity Analysis
Authors
Karthik Sankaranarayanan - Presenter, Massachusetts Institute of Technology
Chaitan Khosla, Stanford University
Camilla M. Kao, Stanford University
Xirui X. Antaris*, Stanford University
Brad A. Palanski, Stanford University
Abrahim El Gamal, Stanford University
William L. Fitch, Stanford University
Curt R. Fischer, Stanford University
The Lipid A family of glycolipids, found in the outer membranes of all Gram-negative bacteria, exhibits considerable structural diversity in both lipid and glycan moieties. The lack of facile methods to prepare analogs of these natural products represents a major roadblock in understanding the relationship between their structure and immunomodulatory activities. Here we present a modular, cell-free multi-enzymatic platform to access these structure-activity relation-ships. By individually purifying 19 Escherichia coli proteins and reconstituting them in vitro in the presence of acetyl-CoA, UDP-N-acetylglucosamine, NADPH, and ATP, we have developed a system capable of synthesizing Lipid IVA, the first bioactive intermediate in the Lipid A pathway. Our reconstituted multi-enzyme system revealed considerable promiscuity for orthologs with distinct substrate specificity, as illustrated by swapping enzymes from distantly related cyanobacterial and Pseudomonas species. Analysis of the agonistic and antagonistic activities of the resulting products against the THP-1 human monocytic cell line revealed hitherto unrecognized trends, while opening the door to harnessing the potent biological activities of these complex glycolipid natural products.

